Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | Director | November 29, 2024 | December 03, 2024 |
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Director | June 10, 2022 | June 28, 2022 |
| NovoCure LtdNVCR · Entity 4494 | Director · Executive Chairman | March 03, 2026 | March 05, 2026 |
| OptiNose, Inc.OPTN · Entity 79464 | Director | June 10, 2020 | June 12, 2020 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,499 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Grant · Acquired 18,169 · Balance 94,499 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
Minerva Neurosciences, Inc.
Report date June 10, 2022 · Filed June 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2032-06-09 | Direct | 2,500 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 2,500 · Balance 2,500 F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year. F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year.
F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split.
F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
NovoCure Ltd
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
After 2026-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 200,000 · Balance 200,000 F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 400,284 |
Reported balance
After 2026-03-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-03 · Grant · Acquired 200,284 · Balance 400,284 F2: Represents vesting of performance-based restricted stock units. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 349,727 |
Reported balance
After 2026-03-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-03-03 · Sale · Disposed 50,557 · Balance 349,727 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 328,397 |
Reported balance
After 2026-03-03 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-03-03 · Sale · Disposed 21,330 · Balance 328,397 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 258,445 |
Reported balance
After 2026-03-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-03 · Grant · Acquired 258,445 · Balance 258,445 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 288,517 |
Reported balance
After 2026-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-03 · Grant · Acquired 30,072 · Balance 288,517 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
F2: Represents vesting of performance-based restricted stock units.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.
F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.
F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
OptiNose, Inc.
Report date June 10, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2030-06-09 | Direct | 14,439 |
Reported balance
After 2020-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-10 · Grant · Acquired 14,439 · Balance 14,439 F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer.
PROKIDNEY CORP.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28 | Direct | 135,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2019 Filed May 6, 2019 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 29,966 | $45.21 | $1,354,643.00 |
DisclosureSEC source: 0001209191-19-027818 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,205 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027818 · doc4.xml · derivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,911 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $43.28 | $2,543,479.04 |
DisclosureSEC source: 0001209191-19-027818 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Adjusted to remove shares erroneously reported as directly held on a prior Form 4. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 44,953 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001209191-19-021326 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,953 Underlying: Ordinary Shares · 44,953 shares Expires 2029-03-21 F2 · derivative.exercise_date: Options to buy 44,953 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 24,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021326 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,860 F1 · shares: Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,097 | $53.68 | $166,246.96 |
DisclosureSEC source: 0001209191-19-015043 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,306 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 9,260 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015043 · doc4.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,518 Underlying: Ordinary Shares · 9,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,260 | $52.90 | $489,854.00 |
DisclosureSEC source: 0001209191-19-015043 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 21:43 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 2,000 | $6.50 | $13,000.00 |
DisclosureSEC source: 0001209191-18-064104 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,611 Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:18 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 4,000 | $7.95 | $31,800.00 |
DisclosureSEC source: 0001209191-18-062261 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,611 Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 22:18 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 2,000 | $8.00 | $16,000.00 |
DisclosureSEC source: 0001209191-18-062261 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,611 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 21:07 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 2,000 | $8.20 | $16,400.00 |
DisclosureSEC source: 0001209191-18-059709 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,611 Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 20:36 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 600 | $10.00 | $6,000.00 |
DisclosureSEC source: 0001209191-18-054978 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,611 Read SEC document |
| September 17, 2018 Filed Sep 19, 2018 20:48 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 1,800 | $10.50 | $18,900.00 |
DisclosureSEC source: 0001209191-18-051657 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,011 Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 20:36 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 200 | $10.50 | $2,100.00 |
DisclosureSEC source: 0001209191-18-051204 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,211 Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 20:36 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 2,000 | $10.50 | $21,000.00 |
DisclosureSEC source: 0001209191-18-051204 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,011 Read SEC document |
| September 11, 2018 Filed Sep 11, 2018 23:32 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 4,011 | $9.72 | $38,986.92 |
DisclosureSEC source: 0001209191-18-050573 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,011 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.50 to $9.95, inclusive. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 23:32 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 4,000 | $9.88 | $39,520.00 |
DisclosureSEC source: 0001209191-18-050573 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.75 to $10.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| August 02, 2018 Filed Aug 20, 2018 20:05 UTC | NovoCure Ltd NVCR · Entity 4494 | OtherOrdinary Shares | 187,787 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-022801 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · WFD-GP II, LLC Disclosed balance after: 438,167 F1 · kind: On August 2, 2018, WFD-GP II LLC distributed to certain of its economic members 187,787 of the Issuer's shares. None of the shares were distributed to Mr. Doyle. F1 · ownership.nature: On August 2, 2018, WFD-GP II LLC distributed to certain of its economic members 187,787 of the Issuer's shares. None of the shares were distributed to Mr. Doyle. F2 · ownership.nature: Mr. Doyle is the Managing Director of WFD Ventures LLC, the sole member of WFD-GP II LLC, which is the general partner of WFD Ventures Fund II, L.P. Mr. Doyle disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 20:59 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001209191-18-045008 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-08-01 F1 · derivative.exercise_date: This option shall vest quarterly over one year commencing on August 1, 2018. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionWarrants · Derivative | 2,330 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-18-043088 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,330 shares Expires 2018-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercisable at any time through July 21, 2018 Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,330 | $3.59 | $8,364.70 |
DisclosureSEC source: 0001209191-18-043088 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 17:16 UTC | OptiNose, Inc. OPTN · Entity 79464 | OtherWarrant (Right to Buy) · Derivative | 1,488,366 | $0.00 Strike: $8.16 | $0.00 |
DisclosureSEC source: 0001494650-18-000080 · wf-form4_153056616389790.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: TKWD Ventures LLC Disclosed balance after: 0 Underlying: Common Stock · 1,488,366 shares Expires 2020-11-01 F1 · kind: TKWD Ventures LLC distributed these shares to its members on a pro rata basis, for no consideration. F4 · derivative.exercise_date: All warrants are currently exercisable. F5 · balance_after: WFD Ventures LLC is the general partner of TKWD Ventures LLC and owns an approximately 10% interest therein. WFD Ventures LLC therefore received 158,571 warrants to purchase shares of Optinose common stock distributed by TKWD Ventures LLC and now owns those warrants directly. F3 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the general partner of TKWD Ventures LLC. Mr. Doyle possesses sole voting and investment power over shares owned by TKWD Ventures LLC. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 17:16 UTC | OptiNose, Inc. OPTN · Entity 79464 | OtherCommon Stock | 2,195,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-18-000080 · wf-form4_153056616389790.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · TKWD Ventures LLC Disclosed balance after: 817,225 F1 · kind: TKWD Ventures LLC distributed these shares to its members on a pro rata basis, for no consideration. F2 · balance_after: WFD Ventures LLC is the general partner of TKWD Ventures LLC and owns an approximately 10% interest therein. WFD Ventures LLC therefore received 221,288 shares of Optinose common stock distributed by TKWD Ventures LLC and now owns those shares directly. Additionally, WFD Ventures LLC may be deemed to have sole voting and investment power over the 817,225 shares owned by TKWD Ventures LLC following the distribution of shares reported herein. F3 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the general partner of TKWD Ventures LLC. Mr. Doyle possesses sole voting and investment power over shares owned by TKWD Ventures LLC. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 17:27 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 14,439 | $22.50 Strike: $22.50 | $324,877.50 |
DisclosureSEC source: 0001494650-18-000067 · wf-form4_152875243612590.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,439 Underlying: Common Stock · 14,439 shares Expires 2028-06-06 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 7, 2019 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2019 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:34 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.25 | $0.00 |
DisclosureSEC source: 0001209191-18-036966 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 7, 2018 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| May 09, 2018 Filed May 10, 2018 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 28,652 | $28.26 | $809,619.56 |
DisclosureSEC source: 0000899243-18-012335 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912,143 F1 · shares: 293,840 restricted stock units ("RSUs") vested on May 2, 2018. The issuer released one-fifth of the RSUs (58,768 RSUs) as of May 3, 2018 (previously reported on a Form 4 filed on May 4, 2018), released one-fifth of the RSUs as of May 4, 2018 and one-fifth of the RSUs as of May 7, 2018 (previously reported on a Form 4 filed on May 8, 2018), and released an additional one-fifth of the RSUs as of May 8, 2018 and one-fifth of the RSUs as of May 9, 2018. Mr. Doyle has sold sufficient RSUs to cover the tax liability. One-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. F2 · shares: Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 28,756 | $28.06 | $806,749.58 |
DisclosureSEC source: 0000899243-18-012335 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,795 F1 · shares: 293,840 restricted stock units ("RSUs") vested on May 2, 2018. The issuer released one-fifth of the RSUs (58,768 RSUs) as of May 3, 2018 (previously reported on a Form 4 filed on May 4, 2018), released one-fifth of the RSUs as of May 4, 2018 and one-fifth of the RSUs as of May 7, 2018 (previously reported on a Form 4 filed on May 8, 2018), and released an additional one-fifth of the RSUs as of May 8, 2018 and one-fifth of the RSUs as of May 9, 2018. Mr. Doyle has sold sufficient RSUs to cover the tax liability. One-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. F2 · shares: Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017. Read SEC document |
| May 07, 2018 Filed May 8, 2018 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 28,804 | $28.01 | $806,771.24 |
DisclosureSEC source: 0000899243-18-011901 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,551 F1 · shares: 293,840 restricted stock units ("RSUs") vested on May 2, 2018. The issuer released one-fifth of the RSUs (58,768 RSUs) as of May 3, 2018 (previously reported on a Form 4 filed on May 4, 2018), released an additional one-fifth of the RSUs as of May 4, 2018 and one-fifth of the RSUs as of May 7, 2018, and will release the other two-fifths on two separate dates hereafter. Mr. Doyle has sold sufficient RSUs to cover the tax liability. After the 293,840 RSUs have been released, one-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. F2 · shares: Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017. Read SEC document |
| May 04, 2018 Filed May 8, 2018 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 28,666 | $27.89 | $799,552.07 |
DisclosureSEC source: 0000899243-18-011901 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 998,355 F1 · shares: 293,840 restricted stock units ("RSUs") vested on May 2, 2018. The issuer released one-fifth of the RSUs (58,768 RSUs) as of May 3, 2018 (previously reported on a Form 4 filed on May 4, 2018), released an additional one-fifth of the RSUs as of May 4, 2018 and one-fifth of the RSUs as of May 7, 2018, and will release the other two-fifths on two separate dates hereafter. Mr. Doyle has sold sufficient RSUs to cover the tax liability. After the 293,840 RSUs have been released, one-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. F2 · shares: Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017. Read SEC document |
| May 03, 2018 Filed May 4, 2018 20:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 28,519 | $27.89 | $795,280.83 |
DisclosureSEC source: 0000899243-18-011533 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,021 F1 · shares: The acquisition of 293,840 ordinary shares resulted from the vesting of an equal number of restricted stock units ("RSUs") on May 2, 2018. The issuer will release one-fifth of the RSUs (58,768 RSUs) as of the date hereof, and will release the other four-fifths on four separate dates hereafter. Mr. Doyle has sold sufficient RSUs to cover the tax liability. After the 293,840 RSUs have been released, one-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. F2 · shares: Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of fully-vested restricted stock units ("RSUs") granted by the issuer to the reporting person and reported on a Form 4 filed on May 4, 2017. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 293,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011533 · doc4.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,679 Underlying: Ordinary Shares · 881,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: RSU represents the right to receive, at settlement, one (1) ordinary share. F1 · derivative.exercise_date: The acquisition of 293,840 ordinary shares resulted from the vesting of an equal number of restricted stock units ("RSUs") on May 2, 2018. The issuer will release one-fifth of the RSUs (58,768 RSUs) as of the date hereof, and will release the other four-fifths on four separate dates hereafter. Mr. Doyle has sold sufficient RSUs to cover the tax liability. After the 293,840 RSUs have been released, one-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. F1 · derivative.expiration_date: The acquisition of 293,840 ordinary shares resulted from the vesting of an equal number of restricted stock units ("RSUs") on May 2, 2018. The issuer will release one-fifth of the RSUs (58,768 RSUs) as of the date hereof, and will release the other four-fifths on four separate dates hereafter. Mr. Doyle has sold sufficient RSUs to cover the tax liability. After the 293,840 RSUs have been released, one-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 293,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-011533 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,055,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The acquisition of 293,840 ordinary shares resulted from the vesting of an equal number of restricted stock units ("RSUs") on May 2, 2018. The issuer will release one-fifth of the RSUs (58,768 RSUs) as of the date hereof, and will release the other four-fifths on four separate dates hereafter. Mr. Doyle has sold sufficient RSUs to cover the tax liability. After the 293,840 RSUs have been released, one-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. F4 · shares: RSU represents the right to receive, at settlement, one (1) ordinary share. F1 · price: The acquisition of 293,840 ordinary shares resulted from the vesting of an equal number of restricted stock units ("RSUs") on May 2, 2018. The issuer will release one-fifth of the RSUs (58,768 RSUs) as of the date hereof, and will release the other four-fifths on four separate dates hereafter. Mr. Doyle has sold sufficient RSUs to cover the tax liability. After the 293,840 RSUs have been released, one-half of the remaining RSUs is scheduled to vest on each of May 2, 2019 and May 2, 2020, subject to Mr. Doyle's continued employment through such dates, pursuant to his Restricted Share Unit Award Notice with NovoCure Limited, dated as of May 2, 2017. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 27,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-014994 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,778 Underlying: Ordinary Shares · 27,778 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 202,758 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-18-014994 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,758 Underlying: Ordinary Shares · 202,758 shares Expires 2028-02-27 F1 · derivative.exercise_date: Options to buy 202,758 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionWarrants · Derivative | 1,549 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-18-005099 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,549 shares Expires 2018-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercisable at any time through January 22, 2018 Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,549 | $3.59 | $5,560.91 |
DisclosureSEC source: 0001209191-18-005099 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2017 Filed Dec 12, 2017 21:47 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantOption Grant (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001209191-17-065214 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-12-10 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments commencing on the date one month following December 10, 2017, subject to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries C-2 Convertible Preferred Stock · Derivative | 92,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 10 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · TKWD Ventures LLC Disclosed balance after: 0 Underlying: Common Stock · 267,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the general partner of TKWD Ventures LLC. Mr. Doyle possesses sole voting and investment power over shares owned by TKWD Ventures LLC. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries C-1 Convertible Preferred Stock · Derivative | 190,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 9 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · TKWD Ventures LLC Disclosed balance after: 0 Underlying: Common Stock · 549,971 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the general partner of TKWD Ventures LLC. Mr. Doyle possesses sole voting and investment power over shares owned by TKWD Ventures LLC. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries C Convertible Preferred Stock · Derivative | 41,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 8 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · TKWD Ventures LLC Disclosed balance after: 0 Underlying: Common Stock · 118,865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the general partner of TKWD Ventures LLC. Mr. Doyle possesses sole voting and investment power over shares owned by TKWD Ventures LLC. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries B-2 Convertible Preferred Stock · Derivative | 719,225 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 7 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · TKWD Ventures LLC Disclosed balance after: 0 Underlying: Common Stock · 2,077,049 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the general partner of TKWD Ventures LLC. Mr. Doyle possesses sole voting and investment power over shares owned by TKWD Ventures LLC. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries D Convertible Preferred Stock · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries C-2 Convertible Preferred Stock · Derivative | 473 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,365 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries C-1 Convertible Preferred Stock · Derivative | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionSeries B-2 Convertible Preferred Stock · Derivative | 4,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,177 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionCommon Stock | 3,013,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · TKWD Ventures LLC Disclosed balance after: 3,013,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of Common Stock received upon conversion of Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: Mr. Doyle is a managing director of WFD Ventures LLC, which is the general partner of TKWD Ventures LLC. Mr. Doyle possesses sole voting and investment power over shares owned by TKWD Ventures LLC. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 16:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | ConversionCommon Stock | 18,803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-062949 · a4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of Common Stock received upon conversion of Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock converted into Common Stock on a 2.8879-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B-2, Series C, Series C-1, Series C-2 and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 20:23 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionWarrants · Derivative | 6,498 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-17-040138 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,498 shares Expires 2017-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercisable at any time through July 31, 2017 Read SEC document |
| June 14, 2017 Filed Jun 15, 2017 20:23 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,498 | $3.59 | $23,327.82 |
DisclosureSEC source: 0001209191-17-040138 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.